Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Net Income towards Common Stockholders (2016 - 2017)

Historic Net Income towards Common Stockholders for Bone Biologics (BBLG) over the last 2 years, with Q4 2017 value amounting to -$2.8 million.

  • Bone Biologics' Net Income towards Common Stockholders rose 4105.06% to -$2.8 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$7.1 million, marking a year-over-year increase of 7275.14%. This contributed to the annual value of -$1.6 million for FY2021, which is 1172.83% up from last year.
  • According to the latest figures from Q4 2017, Bone Biologics' Net Income towards Common Stockholders is -$2.8 million, which was up 4105.06% from -$2.4 million recorded in Q3 2017.
  • In the past 5 years, Bone Biologics' Net Income towards Common Stockholders ranged from a high of $1.0 million in Q2 2017 and a low of -$12.3 million during Q1 2016